Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Targeted exon skipping to address "leaky" mutations in the dystrophin gene.

Fletcher S, Adkin CF, Meloni P, Wong B, Muntoni F, Kole R, Fragall C, Greer K, Johnsen R, Wilton SD.

Mol Ther Nucleic Acids. 2012 Oct 16;1:e48. doi: 10.1038/mtna.2012.40.

2.

Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.

Anthony K, Cirak S, Torelli S, Tasca G, Feng L, Arechavala-Gomeza V, Armaroli A, Guglieri M, Straathof CS, Verschuuren JJ, Aartsma-Rus A, Helderman-van den Enden P, Bushby K, Straub V, Sewry C, Ferlini A, Ricci E, Morgan JE, Muntoni F.

Brain. 2011 Dec;134(Pt 12):3547-59. doi: 10.1093/brain/awr291. Epub 2011 Nov 18.

3.

Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.

Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC.

Neuromuscul Disord. 2002 Oct;12 Suppl 1:S71-7.

PMID:
12206800
4.

Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy.

Wilton SD, Fletcher S.

Curr Pharm Des. 2010;16(8):988-1001. Review.

PMID:
20041827
5.

Targeted exon skipping to correct exon duplications in the dystrophin gene.

Greer KL, Lochm├╝ller H, Flanigan K, Fletcher S, Wilton SD.

Mol Ther Nucleic Acids. 2014 Mar 18;3:e155. doi: 10.1038/mtna.2014.8.

6.

Antisense suppression of donor splice site mutations in the dystrophin gene transcript.

Fletcher S, Meloni PL, Johnsen RD, Wong BL, Muntoni F, Wilton SD.

Mol Genet Genomic Med. 2013 Sep;1(3):162-73. doi: 10.1002/mgg3.19. Epub 2013 Jun 13.

7.

Personalised genetic intervention for Duchenne muscular dystrophy: antisense oligomers and exon skipping.

Mitrpant C, Fletcher S, Wilton SD.

Curr Mol Pharmacol. 2009 Jan;2(1):110-21. Review.

PMID:
20021451
8.

Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switching.

Fragall CT, Adams AM, Johnsen RD, Kole R, Fletcher S, Wilton SD.

BMC Med Genet. 2011 Oct 20;12:141. doi: 10.1186/1471-2350-12-141.

9.

Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript.

Wilton SD, Fall AM, Harding PL, McClorey G, Coleman C, Fletcher S.

Mol Ther. 2007 Jul;15(7):1288-96. Epub 2007 Feb 6.

PMID:
17285139
10.

Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries.

Adams AM, Harding PL, Iversen PL, Coleman C, Fletcher S, Wilton SD.

BMC Mol Biol. 2007 Jul 2;8:57.

11.

Exon skipping and Duchenne muscular dystrophy: hope, hype and how feasible?

Wilton SD, Fletcher S.

Neurol India. 2008 Jul-Sep;56(3):254-62. Review.

12.

Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping.

Madden HR, Fletcher S, Davis MR, Wilton SD.

Hum Mutat. 2009 Jan;30(1):22-8. doi: 10.1002/humu.20806.

PMID:
18570328
13.

Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.

McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD.

Gene Ther. 2006 Oct;13(19):1373-81. Epub 2006 May 25.

PMID:
16724091
14.

Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse.

Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, Moulton HM, Iversen PL, Wilton SD.

Mol Ther. 2007 Sep;15(9):1587-92. Epub 2007 Jun 19.

PMID:
17579573
15.

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.

Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC.

BMC Med Genet. 2007 Jul 5;8:43.

16.

Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.

Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Wilton SD.

J Gene Med. 2006 Feb;8(2):207-16.

PMID:
16285002
17.

Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping.

Bertoni C, Lau C, Rando TA.

Hum Mol Genet. 2003 May 15;12(10):1087-99.

18.

Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.

van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT, van Ommen GJ.

Hum Mol Genet. 2001 Jul 15;10(15):1547-54.

19.

Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations.

Forrest S, Meloni PL, Muntoni F, Kim J, Fletcher S, Wilton SD.

Neuromuscul Disord. 2010 Dec;20(12):810-6. doi: 10.1016/j.nmd.2010.07.276.

20.

Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.

Errington SJ, Mann CJ, Fletcher S, Wilton SD.

J Gene Med. 2003 Jun;5(6):518-27.

PMID:
12797117
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk